Results 31 to 40 of about 6,427,330 (272)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma

open access: yesPathology and Oncology Research, 2023
Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Hongyu Wang   +4 more
doaj   +1 more source

Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy

open access: yesRare Tumors, 2015
We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha   +2 more
doaj   +1 more source

Cutaneous lesions as presentation form of mantle cell lymphoma

open access: yesDermatology Reports, 2011
Mantle cell lymphoma is a type of no-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Here we report a case of mantle cell lymphoma IV Ann Arbor stage with cutaneous lesions on nasal dorsum and ...
Nayra Merino de Paz   +6 more
doaj   +1 more source

Bilateral vision loss as the initial presentation for central nervous system involvement of mantle cell lymphoma: A case series

open access: yesAmerican Journal of Ophthalmology Case Reports, 2021
Purpose: Mantle cell lymphoma is a rare aggressive subtype of non-Hodgkins B cell lymphoma. It typically presents with asymptomatic monoclonal lymphocytosis, lymphadenopathy or bulky extranodal disease.
L. Small   +4 more
doaj   +1 more source

Precision Matters: Minor Concentration Deviations of DMSO May Cause Major Efficacy Shifts

open access: yesAngewandte Chemie, EarlyView.
Low‐concentration dimethyl sulfoxide (DMSO) has long been regarded as biologically safe in drug discovery. However, increasing DMSO from 0.1% to 0.9% reduces photosensitizer PNA‐9 particle size from 657 nm to 260 nm, enhancing endocytosis and photodynamic therapy outcomes.
Sisi Yuan   +6 more
wiley   +2 more sources

DO DIAGNÓSTICO DIFERENCIAL ÀS COMPLICAÇÕES INFECCIOSAS: UM CASO INCOMUM DE LINFOMA DE CÉLULAS DO MANTO - RELATO DE CASO

open access: yesHematology, Transfusion and Cell Therapy
Introdução: O linfoma de células do manto (LCM) é uma neoplasia linfoide B agressiva, caracterizada habitualmente por acometimento linfonodal, esplênico, medular e/ou extranodal.
Caio César DE LIMA SILVA   +9 more
doaj   +1 more source

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

open access: yesHaematologica, 2010
Background The deregulation of several transcription factors contribute to the aggressive course of mantle cell lymphoma. This study focuses on survival signals emanating from the tumor environment and involving the signal transducer and activator of ...
Fanny Baran-Marszak   +10 more
doaj   +1 more source

Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR

open access: yesHaematologica, 2009
Mantle cell lymphoma is characterized by the t(11;14) chromosomal translocation, resulting in the overexpression of cyclin D1 (CycD1). Recently, cases of mantle cell lymphoma negative for cycD1 but positive for cycD2 or cycD3 were identified by gene ...
Leticia Quintanilla-Martinez   +9 more
doaj   +1 more source

Acalabrutinib for mantle cell lymphoma [PDF]

open access: yesBlood, 2019
AbstractMantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a
David Inwards, Thomas E. Witzig
openaire   +2 more sources

Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion

open access: yesCase Reports in Hematology, 2020
Mantle cell lymphoma is a non-Hodgkin lymphoproliferative neoplasm with several clinical and morphologic variants linked, primarily, through genetic derangement of the cyclin D1 locus.
Robert K. McCall   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy